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Abstract
Objective: to evaluate food intake, occurrence of energy-protein malnutrition and anemia, and intestinal iron
absorption in children with chronic liver disease.
Methods: The study included 25 children with chronic liver disease, 14 with cholestasis and 11 without cholestasis.
The age varied between 6.5 months and 12.1 years. Intestinal iron absorption was evaluated by the increment of serum
iron one hour after the ingestion of 1 mg/kg of elemental iron and by the response to oral iron therapy. Iron intestinal
absorption was compared to a group with iron deficiency anemia (without liver disease).
Results: The mean intake of energy and protein in the cholestatic group was higher than in patients without
cholestasis. The nutritional deficit was more severe in cholestatic patients, especially with regard to height-for-age and
weight-for-age indices. Anemia was found in both cholestatic group (11/14; 78.6%) and noncholestatic group (7/11;
63.6%). The cholestatic group presented lower (p < 0.05) intestinal iron absorption (90.6–42.1 µg/dl) than the iron
deficiency anemia group (159.6–69.9 µg/dl). However, cholestatic patients responded to oral iron therapy. The
noncholestatic group showed intestinal iron absorption similar to the iron deficiency anemia group.
Conclusion: The cholestatic group showed more severe nutritional deficits. Despite the evidence of lower iron
intestinal absorption, cholestatic patients responded to oral iron therapy, probably, due to the coexistence of iron
deficiency.
J Pediatr (Rio J). 2005;81(4):317-24: Nutritional status, anemia, intestinal absorption, iron, inflammation, liver
diseases.
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Introduction
Nutritional deficiencies are common among children
with chronic liver disease, especially when the process is
cholestatic and has onset before 6 months.1 Severe protein-
energy malnutrition affects approximately 60% of children
with chronic liver disease,2-5 being secondary to the
interaction of multiple factors, including reduced nutritional
intake, intestinal malabsorption and increased nutrient
requirements due to increased energy expenditure.1,6,7
Despite the knowledge that an adequate nutritional status
contributes towards successful liver transplantation and
lower rates of postoperative complications,5,8-12 studies
performed during transplant pre-op show that a large
proportion of patients with chronic liver disease exhibit
inadequate nutrient intake and protein-energy
malnutrition.6,12
Another common manifestation of chronic liver disease
is anemia. The greater part of what is known about
anemia in chronic liver disease comes from studies of
patients with alcoholic cirrhosis. The principal factors
involved in its genesis are: increased plasma volume,
hemorrhages via esophageal vessels, hemolysis,
deficiencies of elements such as iron, vitamin B-12 and
fo l ic  ac id and abnormal i t ies  l inked to chronic
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inflammation.13 Many of these factors are common to
anemia of chronic inflammation, for which reason it has
been proposed that anemia of chronic liver disease be
included in this syndrome group. In addition to the
reduced life expectancy of blood cells and the reduction in
utilization of iron sequestered within the reticuloendothelial
system, with anemia of chronic inflammation, there can
also be intestinal iron malabsorption. Studies performed
as our service employed the serum iron increase test and
oral iron therapy response test as indicators of intestinal
iron absorption.14,15 It should be pointed out that, as a
result of the elevated prevalence of iron deficiency anemia
in our country, iron deprivation should be considered as
a possible aggravating factor of anemia in children with
chronic liver disease. It should also be remembered that
there is increased intestinal iron absorption with iron
deficiency anemia and that this can be detected by the
serum iron increase test.14,15
Therefore, the objective of this study of children with
chronic liver disease was to evaluate: 1) nutritional intake
nutritional intake; 2) the presence of protein-energy




This was a cross-sectional study, onto which were
enrolled all patients seen at the Hepatology Clinic of the
Universidade Federal de Sªo Paulo  Escola Paulista de
Medicina (UNIFESP/EPM) Pediatric Gastroenterology
Department fulfilling the following inclusion criteria: 1)
suffering from chronic liver disease as characterized by
the following anatomical and pathological findings in liver
biopsy: fibrosis and nodularity, altered hepatic parenchyma
structure and hepatic cell abnormalities, such as
regenerative hyperplasia, pleomorphism and dysplasia16
and 2) no sign of liver decompensation (ascites, edema
and hemorrhage) during the 30 days prior to the study.
The following were not enrolled: 1) auto-immune liver
disease patients of carriers of hepatitis B or C infections;
2) patients who had been given oral iron therapy during
the previous 30 days; 3) patients with hemoglobin levels
below 8 g/dl; 4) patients who had undergone surgery for
biliary atresia less than 6 months previously. Patients
were excluded from the study if they presented infection
during the iron therapy test with ferrous sulphate or if
they received less than 80% of the prescribed iron dose.
In accordance with these procedures, 25 patients
were studied, nine of whom were male and 16 female. Age
varied from 6.5 months to 12.1 years. The median age
(25th and 75th percentiles in parentheses) of patients
with cholestasis was 18 months (14.1-37) and for the
group with no cholestasis this figure was 22.1 months
(15.6-110.6), with the Mann-Whitney test revealing no
difference between the groups (p = 0.366). Depending on
bilirubin, patients were classified as wither cholestatic or
not. Cholestasis was defined as total bilirubin above
2 mg/dl or direct bilirubin accounting for more than 20%
of total bilirubin.17 According to these criteria, 14 patients
were classified as cholestatic and 11 as not suffering from
cholestasis. Seventeen of these patients were diagnosed
as suffering from biliary atresia after at least 6 months of
portoenterostomy, three presented progressive familial
intrahepatic cholestasis (Byler syndrome), one had an
alpha-1-antitrypsin deficiency, one chronic hepatopathy
due to histiocytosis X and three liver diseases with no
definitive etiologic diagnosis.
The study was approved by the UNIFESP/EPM Ethics
Commission. Informed consent in writing was obtained
from the patients parents or guardians.
Methods
Dietary assessment
At the first consultation the childrens mothers were
instructed on how to complete a 72-hour dietary recall,18,19
which they took home to complete. The software program
Sistema de Apoio à Decisªo em Nutriçªo, version 2.5 was
used to calculate energy, protein and iron intake from the
information provided by the dietary recall.20 This program
employs the reference standards for age given in the
Recommended Dietary Allowances, RDA (National Research
Council - NRC, 1989).21
Anthropometry
Weight and stature were measured according to
recommendations made by Jelliffe.22 Patients were measured
unclothed. Weighing was performed using one of two scales
by Filizolafi, either for infants or larger children. For children
younger than 24 months, stature was measured in decubitus
dorsal with an anthropometric ruler with a movable cursor.
Children older than 24 months were measured using a
vertical stadiometer.22
Triceps skin folds (SKF) were measured in millimeters
with a Lange Skinfold Caliper at the posterior superior
region of the relaxed, non-dominant arm at the midpoint of
an imaginary line passing from the acromion to the
olecranon.23 Measurements were repeated three times with
the final result being the mean of the three results to an
accuracy of 0.1 mm.
Mean arm circumference was measured with a non-
stretch measuring tape, encircling the mid portion of the
non-dominant arm, at the midpoint of an imaginary line
joining the acromion to the olecranon with the arm
relaxed.23 Measurements were taken to an accuracy of
0.1 mm.
The formula proposed by Frisancho23 was used to
calculate muscular arm circumference (MAC) based on the
values obtained for TSF and upper arm circumference:
(MAC) (cm) = UAC (cm)  [3.1416 x TSF (mm)]. The
muscular arm area (MAA) was calculated using the formula:
MAA (mm)2 = [(MAC  3.1416) x TSF]2/ 4 x 3.1416.23
Epi-Info version 6.024 software was used to calculate z-
scores for weight-age, weight-stature and stature-age.
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Values below -2 standard deviations were considered
indicative of an anthropometric deficit. Additionally, z-scores
were calculated for TSF, upper arm circumference and arm
muscular area using reference values from Frisancho25 for
children more than 1 year old and values from Sann et al.26
for children less than one.
Laboratory tests
Blood counts were performed by an automated
electronic counter (Cell-Dyn 3500 by Abbott) at the
Hospital Sªo Paulos central laboratory. Anemia was
defined as hemoglobin below 11 g/dl before 4 years of
age, below 11.5 g/dl between 5 and 7 years and 12 g/dl
from 7 to 12 years.27 Serum iron levels were tested by a
colorimetric method (PAK IRONfi by Bayer), transferrin
by the Beckmanfi immunochemical method and ferritin
assay by the immunoenzymometric method (AIA-PACK
FERfi) at the Psychobiology Laboratory at UNIFESP/EPM.
Transferrin saturation was calculated based on values for
serum iron and transferrin. Liver function tests were
performed by conventional methods at the Hospital Sªo
Paulos central laboratory.
Intestinal iron uptake
Serum iron absorption tests were performed after
eight hours fasting.14 A blood sample was taken to
measure base serum iron levels. Immediately after the
fasting sample had been taken, 1 mg of elemental iron
was administered orally per kilo of patient weight in the
form of ferrous sulphate. Two hours after the base level
fasting blood sample had been collected, a second sample
was taken and the serum iron level measured once more.
Intestinal iron intake was based on the increase in serum
iron expressed in µg/dl (serum iron 2 hours after ferrous
sulphate administration minus fasting serum iron level).14
After the baseline tests had been performed, the
treatment test was initiated with ferrous sulphate (Fer-in-
solfi, Mead-Johnson) at a daily dose of 5 mg/kg/day of
elemental iron, divided into two equal parts and given via
the oral route between meals. The medication was provided
to patients and their consumption was gauged according to
the volume consumed after 15 and 30 days iron therapy. On
the thirtieth day of oral iron therapy a blood count was
performed to calculate hemoglobin increase.
For comparison of iron absorption tests (based on
increase in serum iron 2 hours after ferrous sulphate
ingestion) and of ferrous sulphate therapy tests, values
were used that had been observed with 27 children with
iron deficiency anemia and who had undergone the same
diagnostic procedures. These children had been referred
from the walk-in center with suspected iron deficiency
anemia for diagnostic confirmation, intestinal iron uptake
and oral iron therapy assessments as part of their clinical
investigations. Their ages varied from 10 to 78 months,
and 14 of them were male. None of these patients
exhibited or had previously exhibited any clinical evidence
of liver disease.
Statistics
Results were analyzed using both parametric and non-
parametric statistical tests depending on the distribution of
variables. Calculations were run on SigmaStat version 2.0
software. For all tests the null hypothesis rejection point
was set at 5%. The tests used for each analysis are
described together with their results.
Results
Table 1 lists the results of liver function tests for patients
with and without cholestasis. Patients with cholestasis
exhibited higher values, with statistical significance, for
total and direct bilirubin, for aspartate aminotransferase
and for triglycerides, while their albumin was lower than for
the group without cholestasis. Statistical analysis did not
reveal any difference in values for alanine aminotransferase,
alkaline phosphatase, gamma-glutamyl transpeptidase,
prothrombin activity or total proteins.
Table 2 lists nutrient intake according to the 72-hour
dietary recall. Energy and protein intake was lower among
patients without cholestasis. No statistically significant
difference in iron intake was detected, although it should be
pointed out that the median consumption was 57 and 70%,
for patients with and without cholestasis, respectively.
Table 3 lists the anthropometric results. According to the
z-scores, nutritional deficit was more severe, with statistical
significance, among patients with cholestasis, with the
exception of the arm muscle area z-score. The number of
children with a stature deficit for their ages (z-score < -2
standard deviations) was greater (Fishers exact test;
p = 0.042) among patients with cholestasis (9/14; 64.3%)
than among patients without cholestasis (2/11, 18.2%).
The same relationship was observed for weight for age
deficits (p = 0.033), present in 8/14 (57.2%) of the
cholestatic patients and in 1/11 (9.1%) of those without
cholestasis. No statistically significant difference in weight
for stature deficit was observed, with 3/14 (21.4%) and
0/11 (0.0%) suffering this deficiency among patients with
and without cholestasis, respectively.
Table 4 lists indicators for anemia and body iron content.
It was found that hemoglobin and hematocrit levels were
lower among patients with cholestasis than among those
patients without cholestasis. The mean values for mean
corpuscular volume and serum iron were similar for the two
groups. The level of serum ferritin was higher among
children with cholestasis, while transferrin was lower.
Based on hemoglobin levels, anemia was identified in 11
(78.6%) of the 14 cholestatic children and in seven (63.6%)
of the 11 children without cholestasis (Fishers exact test,
p = 0.656).
Table 5 contains the results of the iron absorption test,
initial hemoglobin, hemoglobin on the thirtieth day of oral
iron therapy and the response to oral iron therapy among
the children with chronic liver disease and anemia. For
purposes of comparison, results were used from iron
absorption tests and oral iron therapy response tests of
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27 children with iron deficiency anemia and free of chronic
liver disease who had had their intestinal iron uptake
assessed by the same methods. Patients with liver disease
who did not exhibit anemia were not included in this
analysis, since intestinal iron uptake in individuals with no
iron deficiency is not elevated and, furthermore,
hemoglobin levels would not be expected to increase as a
result of oral iron therapy. The iron absorption test
showed that the intestinal iron uptake of children with
chronic liver disease with cholestasis was inferior to the
iron absorption of the 27 children suffering from iron
deficiency anemia and free from liver disease. It should
be pointed out that, before oral iron therapy, the mean
hemoglobin level of patients with chronic liver disease
and cholestasis was similar to that for the group with iron
deficiency anemia and that levels for both groups were
below the mean of the patients with chronic liver disease,
but no cholestasis. After 30 days of oral iron therapy the
same mean value was observed for the groups with liver
disease without cholestasis and iron deficiency anemia.
With respect of the response to oral iron therapy, it was
observed that patients with liver disease without
cholestasis presented a lower mean hemoglobin increment
than the group with anemia and that this difference was
statistically significant. The paired t test found a statistically
significant hemoglobin increase on the thirtieth day
compared with baseline hemoglobin for all three study
groups.
Table 6 lists body iron content indicators for patients
with liver disease with or without cholestasis and for
children with iron deficiency anemia, but no liver disease.
Although the Kruskal-Wallis test indicated differences in
serum iron levels, the multiple comparisons test did not
confirm this difference. The median for transferrin among
patients with cholestatic liver disease was lower than the
medians for patients with liver disease without cholestasis
Table 1 - Results of liver function tests (median and percentiles 25 and 75 in parenthesis) in patients with
chronic liver disease and with and without cholestasis
Cholestasis p *
Yes (n = 14) No (n = 11)
Aspartate aminotransferase (U/l) 215 (143-244) 85 (71-116) 0.003
Alanine aminotransferase (U/l) 135 (75-187) 67 (55-107) 0.119
Alkaline phosphatase (U/l) 1,708 (938-2,020) 730 (664-1,894) 0.218
Gamma-glutamyl transpeptidase (U/l) 216 (104-351) 228 (141-265) 0.891
Total bilirubin (mg/dl) 9.6 (5-13.1) 1 (0.7-1.5) < 0.001
Direct bilirubin (mg/dl) 6.9 (4-11.6) 0.7 (0.4-0.8) < 0.001
Cholesterol (mg/dl) 203 (140-265) 184 (160-225) 0.848
Triglycerides (mg/dl) 214 (98-239) 135 (62-165) 0.035
Prothrombin activity (%) 77 (39-98) 98 (72-100) 0.147
Total proteins (g/dl) 7.0 (6.3-7.3) 6.7 (6.4-7.8) 0.584
Albumine (g/dl) 3.3 (3-3.7) 3.9 (3.7-4.3) 0.005
* Mann-Whitney’s test.
Table 2 - Nutrient intake (median and percentiles 25 and 75 in parenthesis) according to patients with
chronic liver disease with and without cholestasis
* Mann-Whitney’s test.
Cholestasis p *
Yes (n = 14) No (n = 11)
Energy intake (kcal/kg/dia) 121 (95.8-250.3) 64.4 (58.8-81.4) 0.011
Energy adequated to the RDA (%) 117.4 (93.8-237.4) 71.9 (56-87.9) 0.013
Protein intake (g/kg/dia) 4.6 (3.4-8.2) 3.4 (2.2-3.9) 0.033
Iron intake adequated to the RDA (%) 57.0 (28.5-88.0) 70.0 (55.7-82.0) 0.442
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and with iron deficiency anemia. The median for patients
with cholestatic liver disease was higher than that of the
patients with iron deficiency anemia.
Discussion
Our study, based on anthropometry findings, has shown
that our patients with cholestatic chronic liver disease
exhibited more severe nutritional deficit than did those with
chronic liver disease, but no cholestasis (Table 3). The most
extreme deficit among the cholestatic patients was stature
for age (median z-score = -3.08; with 9/15, 64.3%, below
-2 standard deviations). In this same subset, a significant
deficit in weight for age was also observed, while the deficit
in weight for stature was proportionally less severe (median
z-score = -0.85, with 3/14, 21.4%, below -2 standard
deviations). This nutritional profile is, along general lines,
similar to that observed in other studies in the literature that
assessed the nutritional status of children with chronic
hepatopathy.6,12,28 Theoretically, water retention and
visceromegaly may, at least in part, lead to an
underestimation of weight deficit. In our study patients with
clinical signs of edema or ascites were not included in order
to reduce the influence of this factor on the nutritional
assessment. The laboratory investigation revealed that the
median albumin (3.3 g/dl) of patients with cholestasis was
lower than for the patients without cholestasis (Table 1),
suggesting that patients with cholestasis could have been
suffering from a certain degree of subclinical water retention.
The median transferrin level, which was lower in the group
with cholestasis (Table 4), is probably related to other
factors, in addition to protein-energy malnutrition, such as
the degree of liver failure compromising protein synthesis,
the body iron content and the inflammatory process of the
hepatopathy itself. Observe, in Table 2, that the ingestion
of nutrients by patients with chronic liver disease is greater
among those with cholestasis and that, even so, they exhibit
more severe malnutrition. This result could be explained by
these patients being more compliant with their dietary
guidance. Nevertheless, the median energy intake may yet
Table 3 - Z-scores (median and percentiles 25 and 75 in parenthesis) of the anthropometric resulsts of
patients with chronic liver disease with and without cholsetasis
* Mann-Whitney’s test.
Cholestasis p *
Yes (n = 14) No (n = 11)
Weight-age -2.50 (-3.68; -1.28) -0.65 (-1.38; +0.12) 0.007
Weight-height -0.85 (-1.96; 0.00) -0.04 (-0.33; +0.55) 0.035
Height-age -3.08 (-4.00; -1.27) -0.69 (-1.40; -0.28) 0.009
Triceps skin fold -1.90 (-2.29; -1.42) -0.43 (-0.96; -0.21) 0.001
Arm circumference -2.45 (-4.20; -1.69) -0.54 (-1.28; +1.00) 0.010
Muscular arm area -1.19 (-2.51; 0.00) -0.93(-1.21; -0.23) 0.286
Table 4 - Indicators for anemia and body iron content of patients with chronic liver disease with and without
cholsetasis
* Mean±standard deviation, Student’s t test.
† Median and percentiles 25 and 75 in parenthesis, Mann-Whitney’s test.
Cholestasis p
Yes (n = 14) No (n = 11)
Hemoglobin (g/dl) * 10–1.2 11.2–1 0.011
Hematocrit (%) * 30.7–3.3 33.8–2.6 0.018
Mean corpuscular volume (µ3) * 83.1–12 82.1–5.0 0.796
Serum iron (µg/dl)  55 (38-74) 54 (47-64) 0.784
Transferrin (mg/dl)  258 (220-294) 358 (297-371) 0.003
Transferrin saturation (%)  23.1 (16.4-29) 14.5 (13-22.8) 0.059
Ferritin (ng/ml)  61 (39-137.8) 19 (18.2-46.9) 0.011
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Table 5 - Iron absorption test assessed with the test of serum iron increase and response to oral iron
therapy
Cholestasis Iron deficiency Variance
Yes No anemia analysis
(n = 11) (n = 7) (n = 27)
Iron absorption test (µg/dl) 90.6–42.1 158.0–89.5 159.6–69.9 0.022
Initial hemoglobin (g/dl) 9.6–0.9 10.9–0.7 9.7–1.1 0.030
Final hemoglobin (g/dl) 10.8–1.4 11.6–1.2 11.6–0.9 0.141
Response to oral iron therapy (g/dl) 1.3–1.4 0.7–0.8 1.9–0.9 0.028
Tukeys multiple comparison test:
Iron absorption test
 iron deficiency anemia versus liver disease with cholestasis: p < 0.05
 iron deficiency anemia versus liver disease without cholestasis: p > 0.05
 liver disease with cholestasis versus liver disease without cholestasis: p> 0.05
Initial hemoglobine
 iron deficiency anemia versus liver disease with cholestasis: p > 0.05
 iron deficiency anemia versus liver disease without cholestasis: p < 0.05
 liver disease with cholestasis versus liver disease without cholestasis: p < 0.05
Response to oral iron therapy
 iron deficiency anemia versus liver disease with cholestasis: p > 0.05
 iron deficiency anemia versus liver disease without cholestasis: p < 0.05
 liver disease with cholestasis versus liver disease without cholestasis: p < 0.05
remain below their true requirements, which would be a
possible explanation of the persistent malnutrition. IT
should be pointed out that the present study is not capable
of evaluating the efficacy of nutritional intervention among
patients with chronic liver disease. There is little published
literature on the impact of nutritional intervention on chronic
liver disease. However, studies29,30 do show evident
nutritional recovery after a successful liver transplantation.
These comments indicate the need for improved knowledge
about the alterations to the growth and nutrition of patients
with chronic liver disease so that their nutritional therapy
can be refined. On the other hand, current nutritional
therapy unquestionably represents an advance on the past
and, probably, has reduced the nutritional deficit of these
patients, for which reason it is one of the most important
points in the treatment of children with chronic liver disease.
Triceps skin fold and mean arm circumference deficits
were significantly greater among patients with cholestasis
than those observed in patients without cholestasis (Table
3). This result indicates an accentuated reduction in fat
reserves, as has been described previously12,28 among liver
disease patients, and a tendency to preserve protein reserves
in chronic liver disease malnutrition.6
The iron absorption test, based on serum iron increase
showed that the mean absorption of the group with iron
deficiency anemia was greater than in the group with
cholestatic liver disease (Table 5). In turn, the initial mean
hemoglobin of the group with iron deficiency anemia and the
patients with cholestatic liver disease were very similar, but
lower (p < 0.05) than the mean for the group with liver
disease, but no cholestasis (Table 5). All three groups
exhibited a response to the iron therapy test according to
the paired t test comparing initial hemoglobin levels with the
thirtieth day of oral iron therapy. The mean increase
(0.7–0.8 g/dl) in the group with liver disease, but without
cholestasis was less (p < 0.05) than for the group with iron
deficiency anemia (1.9–0.9 g/dl). Hemoglobin values on
the thirtieth day of oral iron therapy resulted in the same
mean for the groups with iron deficiency anemia and non-
cholestatic liver disease, which mean was not statistically
different from the group with liver disease with cholestasis.
Nevertheless, the mean hemoglobin in the group with
cholestasis was 0.8 g/dl lower than for the other two groups.
Interpreting these results, taking each group as a whole and
not the individual values, allows us to speculate that liver
disease patients without cholestasis present anemia with
iron deficiency as the predominant etiology, considering
their similar iron absorption to the patients with iron
deficiency anemia, the response to iron therapy, which is
lower the higher the baseline hemoglobin value is 15 and the
hemoglobin level on the thirtieth day of iron therapy. In
turn, everything indicates that the group with cholestatic
liver disease also has an inflammatory component to the
etiology of their anemia. This is evidenced by the higher
median ferritin level, lower intestinal iron uptake, according
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Table 6 - Body iron content indicators for patients with anemia and liver disease with or without cholestasis
and for children with iron deficiency anemia, but no liver disease
Cholestasis Iron deficiency
Yes No anemia p
(n = 11) (n = 7) (n = 27)
Serum iron (µg/dL) 48 (39 - 74) 57 (50 - 63) 27 (13 - 65) 0.017
Transferrin (mg/dL) 233 (212 - 294) 358 (297 - 394) 415(352 - 465) < 0.001
Ferritin (ng/ml) 64.3 (45.4 - 123.5) 18.6 (14.8 - 43.8) 2.1 (0.4 - 16.0) < 0.001
Transferrin saturation (%) 21.8 (16.4 24.3) 14.5 (13.8 - 22.8)) 5.6 (3.0 - 16.2 0.002
Dunns multiple comparison test:
Serum iron
 iron deficiency anemia versus liver disease with cholestasis: p > 0.05
 iron deficiency anemia versus liver disease without cholestasis: p < 0.05
 liver disease with cholestasis versus liver disease without cholestasis: p < 0.05
Transferrin
 iron deficiency anemia versus liver disease with cholestasis: p > 0.05
 iron deficiency anemia versus liver disease without cholestasis: p < 0.05
 liver disease with cholestasis versus liver disease without cholestasis: p < 0.05
Ferritin
 iron deficiency anemia versus liver disease with cholestasis: p > 0.05
 iron deficiency anemia versus liver disease without cholestasis: p < 0.05
 liver disease with cholestasis versus liver disease without cholestasis: p < 0.05
Ferritin saturation
 iron deficiency anemia versus liver disease with cholestasis: p > 0.05
 iron deficiency anemia versus liver disease without cholestasis: p < 0.05
 hepatic disease with cholestasis versus hepatic disease without cholestasis: p > 0.05
to serum iron increase, and the lower mean hemoglobin on
the thirtieth day of oral iron therapy. It should be emphasized
that seven of the 11 patients (results not shown) exhibited
an increase in hemoglobin of more than 1 g/dl, demonstrating
the presence of an iron deficiency. Thus, it appears that the
inflammation-dependent component of the anemia is more
intense among the patients with cholestasis than in the
group with liver disease, but no cholestasis. Body iron
content indicators should be interpreted taking account of
the influence of the inflammation, which may result in an
increase in ferritin unrelated to an increase in body iron
reserves. Our results suggest that, in the management of
anemia in patients with chronic liver disease, it is useful to
perform a ferrous sulphate therapy test. It should be
remembered that iron therapy for iron deficiency anemia
should be continued for 2 months after normalization of
hemoglobin in order to complete body iron deposits.14
Finally, it should be emphasized that patients with liver
disease with cholestasis present more severe protein-
energy malnutrition than patients without cholestasis. The
stature for age deficit is the most preeminent. It is necessary
to widen knowledge on this subject, considering the need to
improve the nutritional therapy afforded these patients
since nutritional status is one of the principle prognostic
factors. In turn, anemia is common among patients with
chronic liver disease. Patients with disease without
cholestasis present similar intestinal iron uptake to patients
with iron deficiency anemia. Among patients with cholestasis,
higher levels of ferritin and lower intestinal iron uptake
suggest that, at least in part, anemia is related to
inflammation, while the response to oral iron therapy
indicates a coexisting iron deficiency.
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